ARTICLE | Company News
MethylGene, Pharmion deal
February 6, 2006 8:00 AM UTC
MYG granted PHRM a license to develop and commercialize MGCD0103 and second-generation HDAC inhibitors to treat cancer in North America, Europe, the Middle East and certain other markets. Taiho Pha...